
Novogene said the Pentagon's June 8 designation was 'factually incorrect' and that it has no ties to the Chinese military. It is seeking removal from the list.
Novogene on Monday said the U.S. Department of Defense had "erroneously" placed the Beijing-based genomics company on its Section 1260H list of military-associated firms and that it had started the process to get removed.
The designation, made June 8, is "factually incorrect," the company said in a statement. Novogene called itself an independent publicly listed enterprise with no state ownership or control. It said it does not meet the statutory criteria for the list under the National Defense Authorization Act for Fiscal Year 2021.
"Novogene has no ownership, control, beneficial ownership, affiliation, or relationship whatsoever with any military, intelligence, or other entities as contemplated under Section 1260H," the company said.
The erroneous listing adds Novogene to a Pentagon blacklist that currently includes more than 100 Chinese companies. Being on the list restricts U.S. persons from investing in the designated firms. Several previous designees have successfully petitioned for removal after providing evidence of no military ties.
Novogene said it has engaged with relevant U.S. authorities to clarify the facts and will take all necessary measures to protect the company and its global stakeholders. The firm reaffirmed its commitment to serving life sciences research and clinical markets worldwide and said its operations and partnerships remain fully unaffected.
"We are committed to honoring all existing and future commitments," Novogene said.
The Section 1260H list, established under the 2021 NDAA, is separate from the Commerce Department's Entity List and the Treasury's sanctions lists. Companies can petition for removal by submitting a written statement and supporting documentation to the Pentagon's Defense Office of Hearings and Appeals. The process has no statutory deadline.
Novogene did not specify a timeline for the removal process. The company, which provides genomic sequencing services globally, remains publicly traded.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.